A
Ariel Teper
Researcher at Sanofi S.A.
Publications - 101
Citations - 4961
Ariel Teper is an academic researcher from Sanofi S.A.. The author has contributed to research in topics: Dupilumab & Asthma. The author has an hindex of 20, co-authored 96 publications receiving 3548 citations. Previous affiliations of Ariel Teper include Merck & Co. & Icahn School of Medicine at Mount Sinai.
Papers
More filters
Journal ArticleDOI
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
Mario Castro,Jonathan Corren,Ian D. Pavord,Jorge Maspero,Sally E. Wenzel,Klaus F. Rabe,William W. Busse,Linda B. Ford,Lawrence Sher,J. Mark FitzGerald,Constance H. Katelaris,Yuji Tohda,Bingzhi Zhang,Heribert Staudinger,Gianluca Pirozzi,Nikhil Amin,Marcella Ruddy,Bolanle Akinlade,Asif Khan,Jingdong Chao,Renata Martincova,Neil M.H. Graham,Jennifer D. Hamilton,Brian N. Swanson,Neil Stahl,George D. Yancopoulos,Ariel Teper +26 more
TL;DR: Patients who received dupilumab had significantly lower rates of severe asthma exacerbation than those who received placebo, as well as better lung function and asthma control.
Journal ArticleDOI
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.
Klaus F. Rabe,Parameswaran Nair,Guy Brusselle,Jorge Maspero,Mario Castro,Lawrence Sher,Hongjie Zhu,Jennifer D. Hamilton,Brian N. Swanson,Asif Khan,Asif Khan,Jingdong Chao,Heribert Staudinger,Gianluca Pirozzi,Christian Antoni,Nikhil Amin,Marcella Ruddy,Bolanle Akinlade,Neil M.H. Graham,Neil Stahl,George D. Yancopoulos,Ariel Teper +21 more
TL;DR: In patients with glucocorticoid‐dependent severe asthma, dupilumab treatment reduced oral glucoc Corticoid use while decreasing the rate of severe exacerbations and increasing the FEV1.
Journal ArticleDOI
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
Sally E. Wenzel,Mario Castro,Jonathan Corren,Jorge Maspero,Lin Wang,Bingzhi Zhang,Gianluca Pirozzi,E. Rand Sutherland,Robert Evans,Vijay N. Joish,Laurent Eckert,Neil M.H. Graham,Neil Stahl,George D. Yancopoulos,Mariana Louis-Tisserand,Ariel Teper +15 more
TL;DR: This clinical trial aimed to assess the efficacy and safety of dupilumab as add-on therapy in patients with uncontrolled persistent asthma on medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist, irrespective of baseline eosinophil count.
Journal ArticleDOI
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
Diamant Thaçi,Eric L. Simpson,Lisa A. Beck,Thomas Bieber,Andrew Blauvelt,Kim A. Papp,Weily Soong,Margitta Worm,Jacek C Szepietowski,Howard Sofen,M. Kawashima,Richard Wu,Steven P. Weinstein,Neil M.H. Graham,Gianluca Pirozzi,Ariel Teper,E. Rand Sutherland,Vera Mastey,Neil Stahl,George D. Yancopoulos,Marius Ardeleanu +20 more
TL;DR: Dupilumab improved clinical responses in adults with moderate-to-severe atopic dermatitis in a dose-dependent manner, without significant safety concerns, and shows that IL-4 and IL-13 are key drivers of atopic skinitis.
Journal ArticleDOI
Conjunctivitis in dupilumab clinical trials.
Bolanle Akinlade,Emma Guttman-Yassky,M S de Bruin-Weller,Eric L. Simpson,Andrew Blauvelt,Michael J. Cork,Errol P. Prens,Penny A. Asbell,Esen K. Akpek,Jonathan Corren,Claus Bachert,Claus Bachert,Ikuo Hirano,Jonathan Weyne,Andrew Korotzer,Zhen Chen,Thomas Hultsch,X. Zhu,John D. Davis,Leda Mannent,J. D. Hamilton,Ariel Teper,Heribert Staudinger,E. Rizova,Gianluca Pirozzi,N.M.H. Graham,Brad Shumel,Marius Ardeleanu,Andreas Wollenberg +28 more
TL;DR: Dupilumab blocks the shared receptor component for interleukin (IL)‐4 and IL‐13 and is approved in the U.S.A. for patients aged ≥ 12 years with moderate‐to‐severe atopic dermatitis (AD) uncontrolled by topical prescription medicines or who cannot use topical medicines.